25 XP   0   0   10

Merrimack Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Merrimack together

PenkeI guess you are interested in Merrimack Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Merrimack Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Merrimack Pharmaceuticals Inc

I send you an email if I find something interesting about Merrimack Pharmaceuticals Inc.

Quick analysis of Merrimack (30 sec.)










What can you expect buying and holding a share of Merrimack? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
60.0%

What is your share worth?

Current worth
$1.29
Expected worth in 1 year
$1.15
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.14
Return On Investment
-0.9%

For what price can you sell your share?

Current Price per Share
$15.00
Expected price per share
$14.80 - $15.89
How sure are you?
50%

1. Valuation of Merrimack (5 min.)




Live pricePrice per Share (EOD)

$15.00

Intrinsic Value Per Share

$-26.97 - $38.93

Total Value Per Share

$-25.68 - $40.22

2. Growth of Merrimack (5 min.)




Is Merrimack growing?

Current yearPrevious yearGrowGrow %
How rich?$18.7m$19.2m-$500k-2.7%

How much money is Merrimack making?

Current yearPrevious yearGrowGrow %
Making money-$1.1m-$1.5m$363k30.7%
Net Profit Margin0.0%347.0%--

How much money comes from the company's main activities?

3. Financial Health of Merrimack (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#584 / 1007

Most Revenue
#776 / 1007

Most Profit
#179 / 1007

Most Efficient
#222 / 1007

What can you expect buying and holding a share of Merrimack? (5 min.)

Welcome investor! Merrimack's management wants to use your money to grow the business. In return you get a share of Merrimack.

What can you expect buying and holding a share of Merrimack?

First you should know what it really means to hold a share of Merrimack. And how you can make/lose money.

Speculation

The Price per Share of Merrimack is $15.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Merrimack.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Merrimack, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.29. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Merrimack.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.08-0.5%-0.08-0.5%-0.11-0.7%-0.35-2.3%0.161.1%
Usd Book Value Change Per Share-0.03-0.2%-0.03-0.2%0.352.3%-0.55-3.7%0.432.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.463.1%1.5610.4%
Usd Total Gains Per Share-0.03-0.2%-0.03-0.2%0.352.3%-0.09-0.6%1.9913.3%
Usd Price Per Share13.41-13.41-11.46-7.76-7.62-
Price to Earnings Ratio-165.01--165.01--107.86--66.34--33.59-
Price-to-Total Gains Ratio-389.74--389.74-32.91--74.52--38.31-
Price to Book Ratio10.39-10.39-8.65-6.39-3.20-
Price-to-Total Gains Ratio-389.74--389.74-32.91--74.52--38.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15
Number of shares66
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.46
Usd Book Value Change Per Share-0.03-0.55
Usd Total Gains Per Share-0.03-0.09
Gains per Quarter (66 shares)-2.27-6.06
Gains per Year (66 shares)-9.08-24.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9-19121-146-34
20-18-28243-291-58
30-27-37364-437-82
40-36-46485-582-106
50-45-55607-728-130
60-55-64728-874-154
70-64-73849-1019-178
80-73-82971-1165-202
90-82-911092-1310-226
100-91-1001214-1456-250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%1.014.00.06.7%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%3.012.00.020.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%2.00.03.040.0%6.00.04.060.0%8.00.07.053.3%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.07.00.030.0%4.011.00.026.7%

Fundamentals of Merrimack

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-05-02 23:40:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Merrimack Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Merrimack earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Merrimack to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY347.0%-347.0%
TTM-5Y69.4%-69.4%
5Y69.4%10Y-0.5%+69.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY347.0%-282.4%+629.4%
5Y69.4%-426.4%+495.8%
10Y-0.5%-589.3%+588.8%
1.1.2. Return on Assets

Shows how efficient Merrimack is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Merrimack to the Biotechnology industry mean.
  • -6.2% Return on Assets means that Merrimack generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is -6.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.2%TTM-6.2%0.0%
TTM-6.2%YOY-7.8%+1.6%
TTM-6.2%5Y-30.9%+24.8%
5Y-30.9%10Y-10.0%-20.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.2%-13.0%+6.8%
TTM-6.2%-12.5%+6.3%
YOY-7.8%-11.2%+3.4%
5Y-30.9%-13.6%-17.3%
10Y-10.0%-15.2%+5.2%
1.1.3. Return on Equity

Shows how efficient Merrimack is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Merrimack to the Biotechnology industry mean.
  • -6.3% Return on Equity means Merrimack generated $-0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is -6.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.3%TTM-6.3%0.0%
TTM-6.3%YOY-8.0%+1.7%
TTM-6.3%5Y-34.7%+28.4%
5Y-34.7%10Y24.8%-59.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.3%-16.6%+10.3%
TTM-6.3%-15.7%+9.4%
YOY-8.0%-14.2%+6.2%
5Y-34.7%-18.9%-15.8%
10Y24.8%-19.9%+44.7%

1.2. Operating Efficiency of Merrimack Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Merrimack is operating .

  • Measures how much profit Merrimack makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Merrimack to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY388.5%-388.5%
TTM-5Y77.7%-77.7%
5Y77.7%10Y10.2%+67.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--285.4%+285.4%
TTM--226.2%+226.2%
YOY388.5%-288.4%+676.9%
5Y77.7%-469.6%+547.3%
10Y10.2%-599.3%+609.5%
1.2.2. Operating Ratio

Measures how efficient Merrimack is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-5.885+5.885
TTM-5Y-1.177+1.177
5Y-1.17710Y0.128-1.305
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.303-3.303
YOY-5.8853.763-9.648
5Y-1.1775.586-6.763
10Y0.1287.464-7.336

1.3. Liquidity of Merrimack Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Merrimack is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 43.50 means the company has $43.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 43.501. The company is very able to pay all its short-term debts. +2
  • The TTM is 43.501. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ43.501TTM43.5010.000
TTM43.501YOY33.664+9.837
TTM43.5015Y26.305+17.196
5Y26.30510Y14.526+11.779
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ43.5013.855+39.646
TTM43.5014.160+39.341
YOY33.6645.323+28.341
5Y26.3056.122+20.183
10Y14.5266.480+8.046
1.3.2. Quick Ratio

Measures if Merrimack is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Merrimack to the Biotechnology industry mean.
  • A Quick Ratio of 72.02 means the company can pay off $72.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 72.020. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 72.020. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ72.020TTM72.0200.000
TTM72.020YOY33.003+39.017
TTM72.0205Y30.903+41.118
5Y30.90310Y17.176+13.726
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ72.0203.506+68.514
TTM72.0204.001+68.019
YOY33.0035.390+27.613
5Y30.9036.127+24.776
10Y17.1766.488+10.688

1.4. Solvency of Merrimack Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Merrimack assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Merrimack to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.02 means that Merrimack assets are financed with 2.3% credit (debt) and the remaining percentage (100% - 2.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 0.023. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.023. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.023TTM0.0230.000
TTM0.023YOY0.030-0.007
TTM0.0235Y0.055-0.032
5Y0.05510Y0.832-0.777
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0230.344-0.321
TTM0.0230.339-0.316
YOY0.0300.275-0.245
5Y0.0550.368-0.313
10Y0.8320.389+0.443
1.4.2. Debt to Equity Ratio

Measures if Merrimack is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Merrimack to the Biotechnology industry mean.
  • A Debt to Equity ratio of 2.4% means that company has $0.02 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Merrimack Pharmaceuticals Inc:

  • The MRQ is 0.024. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.024. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.024TTM0.0240.000
TTM0.024YOY0.031-0.007
TTM0.0245Y0.060-0.037
5Y0.06010Y0.103-0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0240.390-0.366
TTM0.0240.408-0.384
YOY0.0310.341-0.310
5Y0.0600.438-0.378
10Y0.1030.469-0.366

2. Market Valuation of Merrimack Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Merrimack generates.

  • Above 15 is considered overpriced but always compare Merrimack to the Biotechnology industry mean.
  • A PE ratio of -165.01 means the investor is paying $-165.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Merrimack Pharmaceuticals Inc:

  • The EOD is -184.570. Based on the earnings, the company is expensive. -2
  • The MRQ is -165.005. Based on the earnings, the company is expensive. -2
  • The TTM is -165.005. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-184.570MRQ-165.005-19.564
MRQ-165.005TTM-165.0050.000
TTM-165.005YOY-107.859-57.146
TTM-165.0055Y-66.343-98.662
5Y-66.34310Y-33.592-32.751
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-184.570-2.351-182.219
MRQ-165.005-2.599-162.406
TTM-165.005-2.762-162.243
YOY-107.859-4.025-103.834
5Y-66.343-6.305-60.038
10Y-33.592-6.538-27.054
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Merrimack Pharmaceuticals Inc:

  • The EOD is -143.217. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -128.036. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -128.036. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-143.217MRQ-128.036-15.181
MRQ-128.036TTM-128.0360.000
TTM-128.036YOY-95.600-32.437
TTM-128.0365Y-101.477-26.560
5Y-101.47710Y-51.459-50.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-143.217-3.010-140.207
MRQ-128.036-3.306-124.730
TTM-128.036-3.607-124.429
YOY-95.600-5.524-90.076
5Y-101.477-8.299-93.178
10Y-51.459-8.910-42.549
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Merrimack is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.39 means the investor is paying $10.39 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Merrimack Pharmaceuticals Inc:

  • The EOD is 11.627. Based on the equity, the company is expensive. -2
  • The MRQ is 10.395. Based on the equity, the company is expensive. -2
  • The TTM is 10.395. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD11.627MRQ10.395+1.232
MRQ10.395TTM10.3950.000
TTM10.395YOY8.652+1.742
TTM10.3955Y6.390+4.004
5Y6.39010Y3.198+3.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.6272.019+9.608
MRQ10.3952.116+8.279
TTM10.3952.099+8.296
YOY8.6522.873+5.779
5Y6.3903.556+2.834
10Y3.1983.946-0.748
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Merrimack Pharmaceuticals Inc.

3.1. Institutions holding Merrimack Pharmaceuticals Inc

Institutions are holding 66.13% of the shares of Merrimack Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Western Standard LLC14.950119.3967217251327850014.7042
2023-12-31Newtyn Management LLC12.89384.9324187369400
2023-12-31BlackRock Inc5.11720.0003743623528067.644
2023-12-31Vanguard Group Inc4.19050.000260895486101.4342
2023-12-31Madison Avenue Partners, LP3.8061.047255308500
2023-12-31ADAR1 Capital Management LLC3.78082.6335494185494180
2023-12-31Dimensional Fund Advisors, Inc.2.99790.0017435645-13107-2.9208
2023-12-31Sepio Capital, LLC2.11040.345530668000
2023-12-31Sio Capital Management, LLC1.98510.880828846600
2023-12-31Geode Capital Management, LLC1.78880.000425994683613.3233
2023-12-31Indaba Capital Management, LLC1.53771.72052234598665763.3448
2023-12-31Wittenberg Investment Management Inc1.44680.97952102395000.2384
2023-12-31State Street Corporation1.35360.000119670548612.5338
2023-12-31Northern Trust Corp0.80450.000311690915401.3348
2023-12-31Morgan Stanley - Brokerage Accounts0.75380.00011095381636117.5591
2023-12-31Bank of New York Mellon Corp0.68950.00031001974940.4955
2023-12-31Susquehanna International Group, LLP0.55490.000280641-76012-48.5225
2023-12-31Goldman Sachs Group Inc0.48440.00017039435441101.3962
2023-12-31Rosalind Advisors, Inc.0.41290.662760000600000
2023-12-31Yakira Capital Management, Inc.0.37240.23645411800
Total 62.031132.83849014224+1014430+11.3%

3.2. Funds holding Merrimack Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Vanguard Total Stock Mkt Idx Inv2.19250.00033186134850.1525
2024-03-28iShares Russell 2000 ETF1.74730.00572539141230.0485
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr1.39970.002920339800
2024-02-29DFA US Micro Cap I0.99890.029814515800
2024-02-29DFA US Small Cap I0.7450.010310825900
2024-01-31Fidelity Small Cap Index0.710.005610317017771.7526
2024-03-28iShares Russell 2000 Growth ETF0.6140.011389226-104-0.1164
2024-02-29Fidelity Extended Market Index0.54480.00379167-384-0.4827
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.42110.00216120000
2024-03-29Dimensional US Targeted Value ETF0.36360.00785283200
2024-03-31Vanguard Russell 2000 ETF0.27490.00583994327997.5355
2023-09-30BlackRock Extended Mkt Composite0.23810.003345951830.5318
2024-02-29Fidelity Total Market Index0.23160.00063365200
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.22780.0053310000
2023-12-31Bridgeway Ultra-Small Company Market0.22360.23463250000
2023-12-31NT R2000 Growth Index Fund - NL0.21630.01143143200
2024-02-29DFA US Core Equity 2 I0.2130.001430958-3816-10.9737
2023-12-31NT R2000 Index Fund - NL0.20750.005630147520.1728
2024-03-31BlackRock Extended Equity Market K0.20590.00329922110.0368
2024-03-31Schwab Small Cap Index0.16480.00582394700
Total 11.94040.3551735133+1126+0.1%

3.3. Insider Transactions

Insiders are holding 1.212% of the shares of Merrimack Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-28Eric AndersenBUY85713.35
2023-12-26Eric AndersenBUY4869313.15
2023-12-07Eric AndersenBUY10105012.85
2023-11-17Eric AndersenBUY30012.5
2023-11-14Eric AndersenBUY5017012.5
2023-08-10Gary L CrockerBUY200012.52
2023-08-07Eric AndersenBUY13449312

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Merrimack Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.034-0.0340%0.348-110%-0.552+1503%0.428-108%
Book Value Per Share--1.2901.2900%1.324-3%1.177+10%-2.049+259%
Current Ratio--43.50143.5010%33.664+29%26.305+65%14.526+199%
Debt To Asset Ratio--0.0230.0230%0.030-23%0.055-58%0.832-97%
Debt To Equity Ratio--0.0240.0240%0.031-23%0.060-61%0.103-77%
Dividend Per Share----0%-0%0.460-100%1.561-100%
Eps---0.081-0.0810%-0.106+31%-0.352+333%0.158-151%
Free Cash Flow Per Share---0.105-0.1050%-0.120+14%-0.543+419%-4.022+3740%
Free Cash Flow To Equity Per Share---0.069-0.0690%0.330-121%-1.029+1394%-5.251+7524%
Gross Profit Margin--2.8412.8410%1.000+184%1.368+108%1.184+140%
Intrinsic Value_10Y_max--38.928--------
Intrinsic Value_10Y_min---26.969--------
Intrinsic Value_1Y_max--0.780--------
Intrinsic Value_1Y_min---3.727--------
Intrinsic Value_3Y_max--4.722--------
Intrinsic Value_3Y_min---10.377--------
Intrinsic Value_5Y_max--11.532--------
Intrinsic Value_5Y_min---16.076--------
Market Cap217977000.000+11%194871438.000194871438.0000%166534428.000+17%112824895.200+73%110746847.800+76%
Net Profit Margin----0%3.470-100%0.694-100%-0.0050%
Operating Margin----0%3.885-100%0.777-100%0.102-100%
Operating Ratio----0%-5.8850%-1.1770%0.128-100%
Pb Ratio11.627+11%10.39510.3950%8.652+20%6.390+63%3.198+225%
Pe Ratio-184.570-12%-165.005-165.0050%-107.859-35%-66.343-60%-33.592-80%
Price Per Share15.000+11%13.41013.4100%11.460+17%7.764+73%7.621+76%
Price To Free Cash Flow Ratio-143.217-12%-128.036-128.0360%-95.600-25%-101.477-21%-51.459-60%
Price To Total Gains Ratio-435.954-12%-389.743-389.7430%32.912-1284%-74.519-81%-38.311-90%
Quick Ratio--72.02072.0200%33.003+118%30.903+133%17.176+319%
Return On Assets---0.062-0.0620%-0.078+26%-0.309+402%-0.100+62%
Return On Equity---0.063-0.0630%-0.080+27%-0.347+450%0.248-125%
Total Gains Per Share---0.034-0.0340%0.348-110%-0.092+167%1.989-102%
Usd Book Value--18747000.00018747000.0000%19247000.000-3%17099800.000+10%-29781700.000+259%
Usd Book Value Change Per Share---0.034-0.0340%0.348-110%-0.552+1503%0.428-108%
Usd Book Value Per Share--1.2901.2900%1.324-3%1.177+10%-2.049+259%
Usd Dividend Per Share----0%-0%0.460-100%1.561-100%
Usd Eps---0.081-0.0810%-0.106+31%-0.352+333%0.158-151%
Usd Free Cash Flow---1522000.000-1522000.0000%-1742000.000+14%-7895000.000+419%-58441500.000+3740%
Usd Free Cash Flow Per Share---0.105-0.1050%-0.120+14%-0.543+419%-4.022+3740%
Usd Free Cash Flow To Equity Per Share---0.069-0.0690%0.330-121%-1.029+1394%-5.251+7524%
Usd Market Cap217977000.000+11%194871438.000194871438.0000%166534428.000+17%112824895.200+73%110746847.800+76%
Usd Price Per Share15.000+11%13.41013.4100%11.460+17%7.764+73%7.621+76%
Usd Profit---1181000.000-1181000.0000%-1544000.000+31%-5895000.000+399%1905900.000-162%
Usd Revenue----0%-445000.0000%-89000.0000%33584200.000-100%
Usd Total Gains Per Share---0.034-0.0340%0.348-110%-0.092+167%1.989-102%
 EOD+5 -3MRQTTM+0 -0YOY+18 -145Y+27 -710Y+20 -15

4.2. Fundamental Score

Let's check the fundamental score of Merrimack Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-184.570
Price to Book Ratio (EOD)Between0-111.627
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than172.020
Current Ratio (MRQ)Greater than143.501
Debt to Asset Ratio (MRQ)Less than10.023
Debt to Equity Ratio (MRQ)Less than10.024
Return on Equity (MRQ)Greater than0.15-0.063
Return on Assets (MRQ)Greater than0.05-0.062
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Merrimack Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5076.437
Ma 20Greater thanMa 5014.756
Ma 50Greater thanMa 10014.730
Ma 100Greater thanMa 20014.107
OpenGreater thanClose15.020
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Depreciation and Amortization  -1,535-745-2,2801,992-288-602-8908922



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets19,188
Total Liabilities441
Total Stockholder Equity18,747
 As reported
Total Liabilities 441
Total Stockholder Equity+ 18,747
Total Assets = 19,188

Assets

Total Assets19,188
Total Current Assets19,184
Long-term Assets4
Total Current Assets
Cash And Cash Equivalents 5,989
Short-term Investments 12,886
Other Current Assets 309
Total Current Assets  (as reported)19,184
Total Current Assets  (calculated)19,184
+/-0
Long-term Assets
Long-term Assets Other 4
Long-term Assets  (as reported)4
Long-term Assets  (calculated)4
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities441
Long-term Liabilities0
Total Stockholder Equity18,747
Total Current Liabilities
Accounts payable 74
Other Current Liabilities 367
Total Current Liabilities  (as reported)441
Total Current Liabilities  (calculated)441
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1,343
Retained Earnings -548,817
Other Stockholders Equity 566,221
Total Stockholder Equity (as reported)18,747
Total Stockholder Equity (calculated)18,747
+/-0
Other
Capital Stock1,343
Cash and Short Term Investments 18,875
Common Stock Shares Outstanding 14,299
Liabilities and Stockholders Equity 19,188
Net Debt -5,989
Net Invested Capital 18,747
Net Working Capital 18,743



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-31
> Total Assets 
0
82,156
57,577
85,299
148,974
192,417
158,656
234,880
81,483
117,326
88,543
20,082
16,776
14,749
19,836
19,188
19,18819,83614,74916,77620,08288,543117,32681,483234,880158,656192,417148,97485,29957,57782,1560
   > Total Current Assets 
0
61,511
36,288
65,589
128,301
166,644
132,096
201,394
57,435
95,046
76,102
18,692
16,544
14,683
19,828
19,184
19,18419,82814,68316,54418,69276,10295,04657,435201,394132,096166,644128,30165,58936,28861,5110
       Cash And Cash Equivalents 
0
58,387
30,713
50,454
37,714
65,086
35,688
185,606
21,524
93,441
20,079
16,580
14,038
14,203
19,439
5,989
5,98919,43914,20314,03816,58020,07993,44121,524185,60635,68865,08637,71450,45430,71358,3870
       Short-term Investments 
0
0
0
0
72,238
90,116
88,340
101
102
102
51,199
0
0
0
0
12,886
12,886000051,19910210210188,34090,11672,2380000
       Net Receivables 
0
1,770
3,745
7,426
9,267
5,857
3,313
6,483
17,469
100
0
0
0
0
0
0
00000010017,4696,4833,3135,8579,2677,4263,7451,7700
       Other Current Assets 
0
1,354
1,830
7,709
8,950
5,484
4,654
5,487
3,786
1,403
4,240
2,112
2,506
480
389
309
3093894802,5062,1124,2401,4033,7865,4874,6545,4848,9507,7091,8301,3540
   > Long-term Assets 
0
20,645
21,289
19,710
20,673
25,773
26,560
33,486
24,048
22,280
12,441
1,390
232
66
8
4
48662321,39012,44122,28024,04833,48626,56025,77320,67319,71021,28920,6450
       Property Plant Equipment 
0
6,491
7,458
6,206
6,297
13,364
14,502
21,915
15,765
6,467
2,269
0
0
0
0
0
000002,2696,46715,76521,91514,50213,3646,2976,2067,4586,4910
       Goodwill 
0
3,605
3,605
3,605
3,605
3,605
3,605
3,605
3,605
0
0
0
0
0
0
0
00000003,6053,6053,6053,6053,6053,6053,6053,6050
       Long Term Investments 
0
0
0
0
0
0
0
0
0
10,551
7,428
0
0
0
0
0
000007,42810,551000000000
       Intangible Assets 
0
10,135
9,815
9,495
9,175
8,045
7,725
7,355
3,977
0
0
0
0
0
0
0
00000003,9777,3557,7258,0459,1759,4959,81510,1350
       Other Assets 
0
0
411
404
596
759
609
611
9,836
5,262
2,744
1,390
232
66
8
0
08662321,3902,7445,2629,83661160975959640441100
> Total Liabilities 
0
272,918
276,514
375,215
155,491
235,882
260,727
418,569
334,142
21,042
29,724
2,770
770
562
589
441
4415895627702,77029,72421,042334,142418,569260,727235,882155,491375,215276,514272,9180
   > Total Current Liabilities 
0
84,094
16,325
26,151
38,520
57,734
111,142
103,746
88,222
19,777
14,795
2,770
770
562
589
441
4415895627702,77014,79519,77788,222103,746111,14257,73438,52026,15116,32584,0940
       Short-term Debt 
0
847
443
48
2,373
8,248
13,346
257,655
47,113
0
0
0
13,346
0
0
0
00013,34600047,113257,65513,3468,2482,373484438470
       Short Long Term Debt 
0
0
0
0
0
0
120,002
257,655
216,861
0
0
0
0
0
0
0
0000000216,861257,655120,002000000
       Accounts payable 
0
2,270
1,440
4,656
24,936
1,889
2,510
5,049
3,384
2,887
1,034
271
123
120
188
74
741881201232711,0342,8873,3845,0492,5101,88924,9364,6561,4402,2700
       Other Current Liabilities 
0
75,507
15,052
27,220
1,861
76,522
72,022
48,560
48,612
16,890
13,761
2,499
647
442
401
367
3674014426472,49913,76116,89048,61248,56072,02276,5221,86127,22015,05275,5070
   > Long-term Liabilities 
0
188,824
260,189
349,064
116,971
177,811
149,585
314,823
245,920
1,265
14,929
271
123
120
589
0
058912012327114,9291,265245,920314,823149,585177,811116,971349,064260,189188,8240
       Long term Debt Total 
0
0
0
0
37,482
103,427
0
257,655
216,861
0
14,873
0
0
0
0
0
0000014,8730216,861257,6550103,42737,4820000
       Other Liabilities 
0
0
68,884
80,839
79,392
74,384
42,779
57,168
29,059
1,265
56
0
0
0
0
0
00000561,26529,05957,16842,77974,38479,39280,83968,88400
       Deferred Long Term Liability 
0
0
0
0
78,192
73,184
35,682
57,168
29,059
1,209
0
0
0
0
0
0
0000001,20929,05957,16835,68273,18478,1920000
> Total Stockholder Equity
0
-190,762
-219,964
-290,490
-6,517
-43,465
-102,140
-183,928
-251,120
96,284
58,819
17,312
16,006
14,187
19,247
18,747
18,74719,24714,18716,00617,31258,81996,284-251,120-183,928-102,140-43,465-6,517-290,490-219,964-190,7620
   Common Stock
0
17,364
111
118
958
1,025
1,067
1,159
1,302
1,334
1,334
1,334
1,334
1,334
1,342
1,343
1,3431,3421,3341,3341,3341,3341,3341,3021,1591,0671,02595811811117,3640
   Retained Earnings Total Equity0-547,6360-543,637-540,609-523,277-482,771-954,799-802,2320-572,245-442,1160000
   Accumulated Other Comprehensive Income 00000-9-32,027-36,215-29,311-74-24-38-16,130-11,124-7,1710
   Capital Surplus 
0
0
0
0
434,679
527,779
0
617,145
702,377
577,721
580,771
556,587
558,309
0
565,541
0
0565,5410558,309556,587580,771577,721702,377617,1450527,779434,6790000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
13,386
51,541
60,231
435,637
527,779
552,037
617,145
702,377
577,721
580,771
556,587
558,309
558,945
565,541
566,221
566,221565,541558,945558,309556,587580,771577,721702,377617,145552,037527,779435,63760,23151,54113,3860



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-2,176
Operating Income-2,176-2,176
 
Operating Expense (+$)
Research Development0
Selling General Administrative2
Selling And Marketing Expenses2,174
Operating Expense2,1762,176
 
Net Interest Income (+$)
Interest Income724
Interest Expense-0
Other Finance Cost-0
Net Interest Income724
 
Pretax Income (+$)
Operating Income-2,176
Net Interest Income724
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,169-3,183
EBIT - interestExpense = -2,178
-1,169
-1,181
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-2,178-1,169
Earnings Before Interest and Taxes (EBITDA)-2,176
 
After tax Income (+$)
Income Before Tax-1,169
Tax Provision-12
Net Income From Continuing Ops-1,433-1,181
Net Income-1,181
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,176
Total Other Income/Expenses Net1,007-724
 

Technical Analysis of Merrimack
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Merrimack. The general trend of Merrimack is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Merrimack's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Merrimack Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 15.89.

The bearish price targets are: 14.91 > 14.83 > 14.80.

Tweet this
Merrimack Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Merrimack Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Merrimack Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Merrimack Pharmaceuticals Inc. The current macd is 0.0740618.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Merrimack price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Merrimack. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Merrimack price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Merrimack Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartMerrimack Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Merrimack Pharmaceuticals Inc. The current adx is 56.57.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Merrimack shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Merrimack Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Merrimack Pharmaceuticals Inc. The current sar is 14.65.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Merrimack Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Merrimack Pharmaceuticals Inc. The current rsi is 76.44. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending down: The RSI is trending down. -1
Merrimack Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartMerrimack Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Merrimack Pharmaceuticals Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Merrimack price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Merrimack Pharmaceuticals Inc Daily Stochastic Oscillator ChartMerrimack Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Merrimack Pharmaceuticals Inc. The current cci is 234.71.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Merrimack Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartMerrimack Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Merrimack Pharmaceuticals Inc. The current cmo is 64.32.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Merrimack Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartMerrimack Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Merrimack Pharmaceuticals Inc. The current willr is -8.10810811.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Merrimack Pharmaceuticals Inc Daily Williams %R ChartMerrimack Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Merrimack Pharmaceuticals Inc.

Merrimack Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Merrimack Pharmaceuticals Inc. The current atr is 0.07878382.

Merrimack Pharmaceuticals Inc Daily Average True Range (ATR) ChartMerrimack Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Merrimack Pharmaceuticals Inc. The current obv is 31,496,067.

Merrimack Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartMerrimack Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Merrimack Pharmaceuticals Inc. The current mfi is 75.92.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Merrimack Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartMerrimack Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Merrimack Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-05-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Merrimack Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Merrimack Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5076.437
Ma 20Greater thanMa 5014.756
Ma 50Greater thanMa 10014.730
Ma 100Greater thanMa 20014.107
OpenGreater thanClose15.020
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Merrimack with someone you think should read this too:
  • Are you bullish or bearish on Merrimack? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Merrimack? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Merrimack Pharmaceuticals Inc

I send you an email if I find something interesting about Merrimack Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Merrimack Pharmaceuticals Inc.

Receive notifications about Merrimack Pharmaceuticals Inc in your mailbox!